The decrease in total revenue was driven mainly by the achievement of non-recurring clinical milestone payments in 2025 of $14.0 million and $3.1 million from GSK and Daiichi Sankyo, respectively
Reciprocal relationship from BMY graph: Reciprocal relationship from ZYME graph: payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predo…
payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w…
payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w…
Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from BMYM…
payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w…
: $ , 2022: $ ) in research and development expense and general and administrative expense accounts. As of December 31, 2024, the total amount contributed by ESPP participants and not yet settled is …
Reciprocal relationship from JAZZ graph: Reciprocal relationship from ZYME graph: : $ , 2022: $ ) in research and development expense and general and administrative expense accounts. As of December 3…
ne Medicines Ltd. (previously known as BeiGene, Ltd.) (“BeOne”): Milestone revenue Recognition of deferred revenue Drug supply Development support payments Royalties Johnson & Johnson Innovative Medi…
Reciprocal relationship from JNJ graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from JNJ grap…
Zymeworks Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ZYME-DEBT
Debt stack $17.0M
90%
Market cache reports total debt of $17.0M.
ZYME-DEBT-13800
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
ZYME-DEBT-13799
Warrants outstanding: 74
90%
xbrl warrant detail from xbrl 2023-12-31.
Zymeworks Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Zymeworks Inc..
Zymeworks Inc. Ownership
Holder
Name
Confidence
Evidence
ZYME-OWNER-ECOR1-CAPITAL-LLC
EcoR1 Capital, LLC
90%
13F overlay lists EcoR1 Capital, LLC as top holder; 221 tracked holders.